Divalproex Sodium Tablet, Delayed Release
Product Images NDC 69452-435

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 69452-435). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Divalproex Sodium De Figure 1)

Chemical structure diagram of divalproex sodium, showing the molecular arrangement with sodium ion and associated groups.*

FDA Label Image

Figure1 (Divalproex Sodium De Figure 2)

A bar chart comparing percentages for two studies labeled 'Study 1 (YMRS)' and 'Study 2 (MRS)'. Each study has two bars: one for PBO and one for DVPX, with values approximately 26%, 60%, 29%, and 58%, respectively.*

FDA Label Image

Figure2 (Divalproex Sodium De Figure 3)

A line graph comparing the percent reduction in complex partial seizures (CPS) rate between divalproex sodium and placebo. The x-axis shows the percentage of patients, and the y-axis shows the percent reduction in CPS, with improvement above and worsening below a no change baseline. The graph features two curves representing divalproex sodium (solid line) and placebo (dashed line).*

FDA Label Image

Figure3 (Divalproex Sodium De Figure 4)

A line graph depicting the cumulative percent reduction in CPS rate among patients treated with divalproex sodium. It compares outcomes for high dose (solid line) versus low dose (dashed line) groups, showing percent of patients on the x-axis and percent reduction in CPS rate on the y-axis, with improvement increasing upward.*

FDA Label Image

Figure4 (Divalproex Sodium De Figure 5)

A bar chart comparing placebo and divalproex sodium across two separate studies, showing numerical values for each group indicating relative outcomes or measurements.*

FDA Label Image

Label1 (Divalproex Sodium De Figure 6)

Label for Divalproex Sodium Delayed-Release Tablets, USP, 125 mg strength, oral tablet form. The label highlights valproic acid activity, specifies 100 tablets per bottle, and states the product is distributed by Bionpharma Inc. It includes storage instructions, drug handling warnings, a barcode, and manufacturing details indicating it is made in India.*

FDA Label Image

Label2 (Divalproex Sodium De Figure 7)

Label for Divalproex Sodium delayed-release tablets, USP, 250 mg, manufactured by Bionpharma Inc. The label includes dosage form information, active ingredient equivalency to valproic acid 250 mg, storage instructions (20° to 25°C), dispensing instructions, and container warnings. It shows a package count of 100 tablets and indicates the product is made in India.*

FDA Label Image

Label3 (Divalproex Sodium De Figure 8)

Label for divalproex sodium delayed-release tablets, USP 500 mg with valproic acid activity. The oral tablet bottle contains 100 tablets and is distributed by Bionpharma Inc. The label specifies storage instructions at controlled room temperature and contraindicates use if the seal is broken. It also includes a caution to keep all drugs out of reach of children and notes the product is made in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.